ATE290014T1 - Festphasen-peptidsynthese - Google Patents

Festphasen-peptidsynthese

Info

Publication number
ATE290014T1
ATE290014T1 AT97939974T AT97939974T ATE290014T1 AT E290014 T1 ATE290014 T1 AT E290014T1 AT 97939974 T AT97939974 T AT 97939974T AT 97939974 T AT97939974 T AT 97939974T AT E290014 T1 ATE290014 T1 AT E290014T1
Authority
AT
Austria
Prior art keywords
peptide synthesis
phase peptide
solid phase
solid
relates
Prior art date
Application number
AT97939974T
Other languages
English (en)
Inventor
Arne Holm
Bjarne Due Larsen
Original Assignee
Zealand Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zealand Pharma As filed Critical Zealand Pharma As
Application granted granted Critical
Publication of ATE290014T1 publication Critical patent/ATE290014T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/042—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers characterised by the nature of the carrier
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Prostheses (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT97939974T 1996-09-09 1997-09-09 Festphasen-peptidsynthese ATE290014T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK97196 1996-09-09
PCT/DK1997/000375 WO1998011125A1 (en) 1996-09-09 1997-09-09 Improved solid-phase peptide synthesis and agent for use in such synthesis

Publications (1)

Publication Number Publication Date
ATE290014T1 true ATE290014T1 (de) 2005-03-15

Family

ID=8099561

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97939974T ATE290014T1 (de) 1996-09-09 1997-09-09 Festphasen-peptidsynthese

Country Status (14)

Country Link
US (1) US7348404B2 (de)
EP (1) EP0929567B1 (de)
JP (1) JP4405594B2 (de)
AT (1) ATE290014T1 (de)
AU (1) AU723268B2 (de)
CA (1) CA2265900C (de)
CZ (1) CZ295838B6 (de)
DE (1) DE69732640T2 (de)
DK (1) DK0929567T3 (de)
ES (1) ES2239364T3 (de)
HU (1) HU230354B1 (de)
IL (1) IL128829A (de)
PT (1) PT929567E (de)
WO (1) WO1998011125A1 (de)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ506839A (en) * 1998-03-09 2003-05-30 Zealand Pharma As Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
US7550425B2 (en) 2000-06-16 2009-06-23 Zealand Pharma A/S Diuretic peptide conjugates
PT1737889E (pt) 2004-10-19 2010-12-13 Lonza Ag Método para síntese de péptidos em fase sólida
UA95235C2 (en) 2005-05-04 2011-07-25 Зииланд Фарма А/С Glucagon-like-peptide-2 (glp-2) analogues
GB0514071D0 (en) 2005-07-07 2005-08-17 Zealand Pharma As N- or C- terminally modified small peptides
US20090171097A1 (en) * 2005-11-22 2009-07-02 Hiroshi Sugiyama Automated solid phase synthesis of pyrrole-imidazole polyamide
UA96283C2 (uk) 2005-12-23 2011-10-25 Зіланд Фарма А/С Модифіковані міметики лізину
KR100859972B1 (ko) * 2006-02-20 2008-09-25 이화여자대학교 산학협력단 막투과 단백질 도메인 펩타이드
DK2000474T3 (en) * 2006-03-29 2018-01-22 Glytech Inc PROCEDURE FOR PRODUCING A PEPTID THIOESTER COMPOUND
CN101573376B (zh) 2006-11-08 2013-11-06 西兰制药公司 选择性胰高血糖素样肽-2（glp-2）类似物
EP2158214B1 (de) 2007-06-15 2011-08-17 Zealand Pharma A/S Glucagonanaloga
JP5635531B2 (ja) 2008-12-15 2014-12-03 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
EP2370462B1 (de) 2008-12-15 2014-07-16 Zealand Pharma A/S Glucagonanaloga
CN102282167B (zh) 2008-12-15 2014-08-13 西兰制药公司 胰高血糖素类似物
ES2477880T3 (es) 2008-12-15 2014-07-18 Zealand Pharma A/S Análogos del glucagón
AU2010272944B2 (en) 2009-07-13 2015-11-19 Zealand Pharma A/S Acylated glucagon analogues
CN107129538B (zh) 2010-04-27 2021-07-16 西兰制药公司 Glp-1受体激动剂和胃泌素的肽缀合物及其用途
UY33462A (es) 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon
US9169310B2 (en) 2010-06-24 2015-10-27 Zealand Pharma A/S Glucagon analogues
KR20140043709A (ko) 2011-01-20 2014-04-10 질랜드 파마 에이/에스 아실화 글루카곤 유사체와 인슐린 유사체의 조합
TW201326194A (zh) 2011-11-03 2013-07-01 Zealand Pharma As Ｇｌｐ－１胃泌素受體促效劑肽結合物
IN2014CN04401A (de) 2011-12-23 2015-09-04 Zealand Pharma As
WO2013098408A1 (en) 2011-12-30 2013-07-04 Zealand Pharma A/S Glucagon and cck receptor agonist peptide conjugates
WO2013113916A2 (en) 2012-02-03 2013-08-08 Zealand Pharma A/S Ghrelin analogues
IN2014MN02304A (de) 2012-05-03 2015-08-07 Zealand Pharma As
CN104540850B (zh) 2012-05-03 2018-05-18 西兰制药公司 胰高血糖素样肽2(glp-2)类似物
IN2015DN00544A (de) 2012-07-23 2015-06-26 Zealand Pharma As
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
EP3666795A1 (de) 2013-03-12 2020-06-17 Molecular Templates, Inc. Zytotoxische proteine mit zellgerichteten bindungsregionen und shigatoxin-a-untereinheitsregionen zur selektiven tötung von spezifischen zellarten
US9695214B2 (en) 2013-03-15 2017-07-04 Massachusetts Institute Of Technology Solid phase peptide synthesis processes and associated systems
US9169287B2 (en) 2013-03-15 2015-10-27 Massachusetts Institute Of Technology Solid phase peptide synthesis processes and associated systems
CA2907454C (en) 2013-03-21 2021-05-04 Sanofi-Aventis Deutschland Gmbh Synthesis of hydantoin containing peptide products
US10450343B2 (en) 2013-03-21 2019-10-22 Sanofi-Aventis Deutschland Gmbh Synthesis of cyclic imide containing peptide products
PL3057984T3 (pl) 2013-10-17 2018-12-31 Zealand Pharma A/S Acylowane analogi glukagonu
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
WO2015067715A2 (en) 2013-11-06 2015-05-14 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
CN105829339B (zh) 2013-11-06 2021-03-12 西兰制药公司 胰高血糖素-glp-1-gip三重激动剂化合物
WO2015100246A1 (en) 2013-12-24 2015-07-02 Ossianix, Inc. Baff selective binding compounds and related methods
CN112851769A (zh) 2014-01-27 2021-05-28 分子模板公司 用于哺乳动物中的去免疫化志贺毒素a亚基效应子多肽
ES2809729T3 (es) 2014-03-11 2021-03-05 Molecular Templates Inc Proteínas que comprenden regiones efectoras de la subunidad A de la toxina Shiga próximas al extremo amino terminal y regiones de unión de tipo inmunoglobulina de reconocimiento celular capaces de unirse específicamente a HER2/neu/ErbB2
JP6935195B2 (ja) 2014-03-11 2021-09-15 モレキュラー テンプレーツ, インク.Molecular Templates, Inc. 結合領域、志賀毒素ａサブユニットのエフェクター領域、及びカルボキシ末端小胞体局在化シグナルモチーフを含むタンパク質
CN106604934A (zh) 2014-06-11 2017-04-26 分子模板公司 耐受蛋白酶切割的志贺毒素a亚基效应子多肽和包含其的细胞靶向分子
EP3160995A2 (de) 2014-06-26 2017-05-03 Ossianix Inc. Halbsynthetische ammenhai-vnar-bibliotheken zur herstellung und verwendung von verbindungen mit selektiver bindung
KR102620911B1 (ko) 2014-10-29 2024-01-05 질랜드 파마 에이/에스 Gip 효능제 화합물 및 방법
EP3218411B1 (de) 2014-11-14 2022-01-12 Ossianix, Inc. Variable neue antigen rezeptoren (vnars) gegen transferrinrezeptor (tfr) und deren verwendung
EP3253799B1 (de) 2015-02-05 2020-12-02 Molecular Templates, Inc. Multivalente cd20-bindende moleküle mit shigatoxin-a-untereinheiteffektorregionen und angereicherte zusammensetzungen davon
BR112017019378A2 (pt) 2015-03-18 2019-02-19 Zealand Pharma A/S análogos de amilina
GB201506380D0 (en) 2015-04-15 2015-05-27 Serodus Asa Materials and methods for treatment of pulmonary hypertension
DK3283507T3 (da) 2015-04-16 2020-01-02 Zealand Pharma As Acyleret glucagonanalog
EP3303373B1 (de) 2015-05-30 2020-04-08 Molecular Templates, Inc. Deimmunisierte shigatoxin-a-untereinheitsgerüste und zellgerichtete moleküle damit
KR20180030085A (ko) 2015-07-26 2018-03-21 몰레큘러 템플레이츠, 인코퍼레이션. 시가 독소 a 서브유닛 작동체 및 cd8+ t-세포 에피토프를 포함하는 세포-표적화 분자
CN108290923A (zh) 2015-09-17 2018-07-17 麻省理工学院 用于固相肽合成的方法和系统
EP3494216B1 (de) 2016-08-06 2025-10-15 Ossianix, Inc. In-vivo-verfahren zur auswahl von peptiden, die die blut-hirn-schranke überwinden, zugehörige zusammensetzungen und verfahren zur verwendung
US10071140B2 (en) 2016-09-09 2018-09-11 Zealand Pharma A/S Amylin analogues
WO2018103868A1 (en) 2016-12-09 2018-06-14 Zealand Pharma A/S Acylated glp-1/glp-2 dual agonists
EP3551651B1 (de) 2016-12-09 2024-03-06 Zealand Pharma A/S Acylierte glp-1/glp-2 duale agoniste
WO2018104559A1 (en) 2016-12-09 2018-06-14 Zealand Pharma A/S Glp-1/glp-2 dual agonists
CA3044915A1 (en) 2016-12-09 2018-06-14 Zealand Pharma A/S Glp-1/glp-2 dual agonists
WO2018104558A1 (en) 2016-12-09 2018-06-14 Zealand Pharma A/S Acylated glp-1/glp-2 dual agonists
MX2019008840A (es) 2017-01-25 2019-09-09 Molecular Templates Inc Moleculas con direccion hacia las celulas que comprenden efectores de la sub-unidad a de la toxina shiga desinmunizados y epitopos de las celulas t cd8+.
IL299864B2 (en) 2017-06-16 2024-06-01 Zealand Pharma As Dosage regimes for the administration of glucagon-like-peptide-2 (glp-2) analogues
WO2019089395A1 (en) 2017-11-02 2019-05-09 Ossianix, Inc. Improved tfr-selective binding peptides capable of crossing the blood brain barrier
RU2020128624A (ru) 2018-02-27 2022-03-28 Зп Спв 3 К/С Аналоги компстатина и их медицинское применение
CN110612117B (zh) 2018-04-17 2024-04-12 分子模板公司 包含去免疫化的志贺毒素a亚基支架的her2靶向分子
US12258414B2 (en) 2018-06-22 2025-03-25 Ossianix, Inc. Anti-CD98hc VNARs for crossing the blood brain barrier and type IV VNAR libraries
CN119264211A (zh) 2018-08-27 2025-01-07 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用
WO2020056327A1 (en) 2018-09-14 2020-03-19 Ossianix, Inc. Tfr-specific binding moieties and transcytosis method to select vnars that cross cellular barriers
WO2020081493A1 (en) 2018-10-16 2020-04-23 Molecular Templates, Inc. Pd-l1 binding proteins
US11414496B2 (en) 2019-01-23 2022-08-16 Takeda Pharmaceutical Company Limited Anti-CD38 binding domains
EP3914610A1 (de) 2019-01-23 2021-12-01 Millennium Pharmaceuticals, Inc. Cd38-bindende proteine mit deimmunisiertem shiga-toxin-a-untereinheitseffektoren
SG11202111311WA (en) 2019-06-14 2021-12-30 Zealand Pharma As Pharmaceutical parenteral composition of dual glp1/2 agonist
BR112022003760A2 (pt) 2019-08-27 2022-05-31 Zp Spv 3 K/S Análogos de compstatina e seus usos médicos
WO2021055816A1 (en) 2019-09-18 2021-03-25 Molecular Templates, Inc. Pd-l1 binding molecules comprising shiga toxin a subunit scaffolds
CA3155089A1 (en) 2019-09-20 2021-03-25 Zealand Pharma A/S Kv1.3 blockers
WO2021102445A1 (en) 2019-11-24 2021-05-27 Molecular Templates, Inc. Uses of cd20-binding molecules and additional therapeutic agents
US20230129788A1 (en) 2020-03-30 2023-04-27 Zealand Pharma A/S Glp-1/glp-2 dual agonists
EP4126004A1 (de) 2020-03-30 2023-02-08 Zealand Pharma A/S Agonistenkombination
IL299870A (en) 2020-07-16 2023-03-01 Zp Spv 3 K/S Complement factor C3 inhibitors and their medical uses
WO2022103769A1 (en) 2020-11-11 2022-05-19 Ossianix, Inc. High affinity human and monkey specific tfr-1 vnars
CA3200526A1 (en) 2020-12-16 2022-06-23 Jesper Skodborg VILLADSEN Pharmaceutical composition of glp-1/glp-2 dual agonists
MX2023006280A (es) 2020-12-16 2023-06-13 Zealand Pharma As Composicion farmaceutica de agonistas duales de glp-1/glp-2.
IL301892A (en) 2020-12-16 2023-06-01 Zealand Pharma As Drug composition of dual GLP-1/GLP-2 agonists
ES3062907T3 (en) 2021-02-18 2026-04-14 Zealand Pharma As Glp-1/glp-2 dual agonist for treating short bowel syndrome
WO2022197945A1 (en) 2021-03-17 2022-09-22 Molecular Templates, Inc. Pd-l1 binding proteins comprising shiga toxin a subunit scaffolds and cd8+ t cell antigens
US20240182531A1 (en) 2021-03-23 2024-06-06 Zealand Pharma A/S KV1.3 Blockers
WO2022260877A1 (en) 2021-06-07 2022-12-15 Ossianix, Inc. Shark vnars for treating covid-19
KR20240022551A (ko) 2021-06-18 2024-02-20 베이징 투오 지에 바이오파마수티컬 컴퍼니 리미티드 글루카곤 유사체 및 이의 의학적 용도
WO2023023166A1 (en) 2021-08-17 2023-02-23 Ossianix, Inc. Deimmunized vnar domains and scaffolds
JP2024533153A (ja) 2021-09-03 2024-09-12 ジーランド ファーマ エー／エス 投薬レジーム
AU2022402440A1 (en) 2021-12-01 2024-05-30 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
WO2024068848A1 (en) 2022-09-28 2024-04-04 Zealand Pharma A/S Methods for treating obesity
JP2025534884A (ja) 2022-10-18 2025-10-20 ジーランド ファーマ エー／エス 阻害剤
WO2024168411A1 (pt) * 2023-02-15 2024-08-22 Proteimax Bio Technology Israel Ltd Aditivo de alimento e/ou suplemento alimentar, processo de obtenção, formulação de alimento funcional e/ou suplemento alimentar, uso
EP4471049A1 (de) 2023-06-01 2024-12-04 Zealand Pharma A/S Peptidinhibitoren des interleukin-23-rezeptors
EP4471048A1 (de) 2023-06-01 2024-12-04 Zealand Pharma A/S Peptidinhibitoren des interleukin-23-rezeptors
WO2025056677A1 (en) 2023-09-15 2025-03-20 Zealand Pharma A/S Dasiglucagon for use in the treatment of congenital hyperinsulinism
WO2025120002A1 (en) 2023-12-04 2025-06-12 Zealand Pharma A/S Petrelintide for reducing weight whilst preserving lean mass
TW202530247A (zh) 2023-12-04 2025-08-01 丹麥商西蘭製藥公司 方法
WO2025248124A1 (en) 2024-05-31 2025-12-04 Zealand Pharma A/S Dapiglutide for use in treating a sub-group of subjects
WO2025259842A2 (en) 2024-06-12 2025-12-18 Invaio Sciences, Inc. Novel alpha-factor based peptides with antifungal activity
WO2025259861A2 (en) 2024-06-12 2025-12-18 Invaio Sciences, Inc. Antimicrobial peptides against citrus greening
WO2025262301A1 (en) 2024-06-20 2025-12-26 Zealand Pharma A/S Petrelintide for use in the treatment of obesity, diabetes or a disease linked to obesity or diabetes, or of reducing body weight, inhibiting weight gain or reducing food intake
WO2026003546A1 (en) 2024-06-27 2026-01-02 Vrg Miniprotein Zrt Potassium ion kv1.3 channel inhibitors
WO2026013260A1 (en) 2024-07-12 2026-01-15 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
WO2026052861A1 (en) 2024-09-09 2026-03-12 Zealand Pharma A/S Treatment with dapiglutide
WO2026052859A1 (en) 2024-09-09 2026-03-12 Zealand Pharma A/S Treatment with dapiglutide

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5116666A (de) * 1974-07-30 1976-02-10 Shionogi Seiyaku Kk
US5021550A (en) * 1986-10-07 1991-06-04 Thomas Jefferson University Method for preventing deletion sequences in solid phase synthesis
JP2807287B2 (ja) * 1989-10-13 1998-10-08 株式会社医学生物学研究所 ペプチドおよびその用途
CA2170030A1 (en) * 1993-09-14 1995-03-23 Robert A. Lazarus Pharmaceutical compositions containing ecotin and homologs thereof
US7176282B1 (en) * 1996-09-09 2007-02-13 Zealand Pharma A/S Solid-phase peptide synthesis and agent for use in such synthesis
NZ506839A (en) * 1998-03-09 2003-05-30 Zealand Pharma As Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis

Also Published As

Publication number Publication date
IL128829A (en) 2005-08-31
JP4405594B2 (ja) 2010-01-27
AU723268B2 (en) 2000-08-24
DK0929567T3 (da) 2005-06-27
EP0929567B1 (de) 2005-03-02
CZ295838B6 (cs) 2005-11-16
HU230354B1 (hu) 2016-02-29
IL128829A0 (en) 2000-01-31
DE69732640D1 (de) 2005-04-07
PT929567E (pt) 2005-07-29
CA2265900C (en) 2007-07-31
HUP0102900A3 (en) 2002-02-28
JP2001500134A (ja) 2001-01-09
AU4199397A (en) 1998-04-02
CZ80399A3 (cs) 1999-08-11
CA2265900A1 (en) 1998-03-19
HUP0102900A2 (hu) 2002-01-28
US20070004905A1 (en) 2007-01-04
DE69732640T2 (de) 2006-01-12
WO1998011125A1 (en) 1998-03-19
US7348404B2 (en) 2008-03-25
EP0929567A1 (de) 1999-07-21
ES2239364T3 (es) 2005-09-16

Similar Documents

Publication Publication Date Title
DE69732640D1 (de) Festphasen-peptidsynthese
ATE271058T1 (de) Mycophenol bisphosponatverbindungen
ATE233277T1 (de) Cyklische peptide, die an den urokinase-type plasminogen aktivator rezeptor binden
DK1144607T3 (da) Fremgangsmåde til præsentation af (poly)peptider/proteiner på bakteriofage partikler via disulfidbindinger
ATE270303T1 (de) Gc1q-rezeptor, daran bindende hiv-1 gp120-region, verwandte peptide und antikörper
BG103091A (en) Shortened soluble receptors of type i & ii of the tumour necrotizing factor
DZ3482A1 (fr) Secretagogues de l'hormone de croissance
TR200000930T2 (tr) Büyüme hormonu sekretagogları.
ATE394482T1 (de) Verfahren und zusammensetzungen für peptid-, protein- und peptidomimetische synthese
SE9903291D0 (sv) New process
FI961044A7 (fi) Kininogeeni-inhibiittorit
AU580350B2 (en) Process for synthesising peptides
FI953525L (fi) Kemiallinen syntetointimenetelmä fibronektiiniä sitovan proteiinin tai polypeptidin valmistamiseksi
IL187595A0 (en) Antitumor antibodies, proteins, and uses thereof
HUT55800A (en) Process for producing anticoagulant peptides
DE69227517D1 (de) Produktion von peptid-amiden
EP1123108A4 (de) Isolierte peptide die an hla-b35 moleküle binden
GR3021660T3 (en) Anticoagulant peptides
SE9800865D0 (sv) New Process
ATE235509T1 (de) Peptide zur inhibition von hpv e7 proteinen
AU2003273953A8 (en) Method for synthesizing peptides comprising at least one glycine molecule
IT1264598B1 (it) Intermedi per la preparazione di peptidi retro-inversi
IT1270613B (it) Lattami biciclici come intermedi per la sintesi di peptidi biologicamente attivi
ATE417105T1 (de) Spleissvariante des kopftrauma induzierten zytoplasmatischen calcium-bindenden proteins

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0929567

Country of ref document: EP